These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15826590)

  • 1. [Palivizumab and bronchiolitis: need to apply the efficiency in order to join clinical practice to scientific studies].
    González de Dios J; Ochoa Sangrador C
    Med Clin (Barc); 2005 Apr; 124(12):478-9. PubMed ID: 15826590
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of palivizumab on admission to the ICU for respiratory syncytial virus bronchiolitis: a national survey.
    Prais D; Danino D; Schonfeld T; Amir J
    Chest; 2005 Oct; 128(4):2765-71. PubMed ID: 16236953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of respiratory syncytial virus infection.
    Kimpen JL
    Curr Opin Infect Dis; 2001 Jun; 14(3):323-8. PubMed ID: 11964851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Practical pediatric aspects of palivizumab].
    Battisti O; Vandenbosch K; Nyaamugabo K; Carvelli T
    Rev Med Liege; 2009; 64(5-6):318-22. PubMed ID: 19642467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory syncytial virus bronchiolitis.
    Leung AK; Kellner JD; Davies HD
    J Natl Med Assoc; 2005 Dec; 97(12):1708-13. PubMed ID: 16396064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High rate of indigenous bronchiolitis and palivuzumab.
    Whitehall JS; Bolisetty S; Whitehall JP; Francis F; Norton R; Patole SK
    J Paediatr Child Health; 2001 Aug; 37(4):416-7. PubMed ID: 11547779
    [No Abstract]   [Full Text] [Related]  

  • 7. Bronchiolitis.
    Worrall G
    Can Fam Physician; 2008 May; 54(5):742-3. PubMed ID: 18474710
    [No Abstract]   [Full Text] [Related]  

  • 8. Economic disadvantages of palivizumab.
    Smith RA; Boon R
    Arch Dis Child; 2000 Apr; 82(4):336. PubMed ID: 10766708
    [No Abstract]   [Full Text] [Related]  

  • 9. Appropriate use of palivizumb (Synagis).
    Graham LM; Lesnick B
    Pediatr Pulmonol Suppl; 2004; 26():156-7. PubMed ID: 15029637
    [No Abstract]   [Full Text] [Related]  

  • 10. [Prevention of respiratory syncytial virus infections with palivizumab].
    Ellingsen BB; Aase SA; Øymar K
    Tidsskr Nor Laegeforen; 2003 Apr; 123(7):941-3. PubMed ID: 12737068
    [No Abstract]   [Full Text] [Related]  

  • 11. Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks.
    Resch B; Gusenleitner W; Müller WD; Haas J
    Eur J Clin Microbiol Infect Dis; 2006 Feb; 25(2):120-2. PubMed ID: 16491302
    [No Abstract]   [Full Text] [Related]  

  • 12. [Palivizumab prophylaxis against respiratory syncytial virus. Should its indications be reviewed?].
    Salas Hernández S
    An Pediatr (Barc); 2004 Jan; 60(1):87-8. PubMed ID: 14718137
    [No Abstract]   [Full Text] [Related]  

  • 13. [Guidelines for respiratory syncytial virus prophylaxis. An update].
    Carbonell-Estrany X; Quero Jiménez J
    An Esp Pediatr; 2002 Apr; 56(4):334-6. PubMed ID: 11927077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Who shall not receive palivizumab?
    Brunvand L; Lindemann R; Grøgaard J
    Pediatrics; 2000 Oct; 106(4):866. PubMed ID: 11183179
    [No Abstract]   [Full Text] [Related]  

  • 15. Guidelines for the use of palivizumab in infants and young children with congenital heart disease.
    Nakazawa M; Saji T; Ichida F; Oyama K; Harada K; Kusuda S
    Pediatr Int; 2006 Apr; 48(2):190-3. PubMed ID: 16635185
    [No Abstract]   [Full Text] [Related]  

  • 16. From chimpanzee coryza to palivizumab: changing times for respiratory syncytial virus.
    Ogra PL
    Pediatr Infect Dis J; 2000 Aug; 19(8):774-9; discussion 811-3. PubMed ID: 10959757
    [No Abstract]   [Full Text] [Related]  

  • 17. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
    Fitzgerald DA
    Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.
    Prais D; Schonfeld T; Amir J;
    Pediatrics; 2003 Sep; 112(3 Pt 1):548-52. PubMed ID: 12949282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats.
    Ottolini MG; Curtis SJ; Porter DD; Mathews A; Richardson JY; Hemming VG; Prince GA
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2299-302. PubMed ID: 12069994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.